Workflow
国际认证
icon
Search documents
天山股份:已取得美国石油学会APIQR证书等多项认证
Sou Hu Cai Jing· 2025-07-30 03:50
Core Viewpoint - Tianshan Co., Ltd. has confirmed its capability to produce API standard oil well cement, having obtained various international certifications, which positions the company as a leader in the specialized cement industry in China [1]. Group 1: Company Capabilities - Tianshan Co., Ltd. is recognized as the domestic company with the most diverse range of cement products and is the largest producer of special and functional cement-based materials [1]. - The company has achieved certifications from the American Petroleum Institute (API), including APIQR, Q1, and TS/29001, demonstrating its compliance with international standards for oil well cement production [1]. Group 2: Industry Context - Oil well cement is identified as a critical foundational material that has developed alongside China's petroleum industry, highlighting the importance of this product in the sector [1].
万泰生物艾滋自检试剂通过世卫组织PQ认证;归创通桥5月9日起摘“B”
Mei Ri Jing Ji Xin Wen· 2025-05-06 23:41
Group 1: WanTai Bio - WanTai Bio announced that its HIV urine self-test kit has received prequalification (PQ) certification from the World Health Organization (WHO), marking it as the first HIV antibody urine self-test kit globally to achieve this status [1] - This certification allows the product to participate in procurement projects by the United Nations and other global multilateral organizations, enhancing the company's international competitiveness [1] - The recognition from WHO is expected to boost investor confidence in the company's research and market potential [1] Group 2: East China Pharmaceutical - East China Pharmaceutical's subsidiary received approval from the National Medical Products Administration (NMPA) for the clinical trial of HDM2005, an antibody-drug conjugate targeting ROR1 for treating diffuse large B-cell lymphoma (DLBCL) [2] - The drug is currently in the fifth dose escalation phase of its clinical trial in China, with no dose-limiting toxicities reported so far [2] - The approval of HDM2005's clinical trial represents a significant advancement in the company's research and development in the oncology field [3] Group 3: GuiChuang TongQiao - GuiChuang TongQiao announced that it will remove the "B" designation from its stock name starting May 9, 2025, indicating that it no longer falls under the category of unprofitable companies [4] - This change reflects the company's achievement of higher operational and performance standards, which is expected to enhance its influence in the capital market and investor recognition [4]